205 related articles for article (PubMed ID: 37276043)
1. The effectiveness and value of fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause: A summary from the Institute for Clinical and Economic Review's Midwest Public Advisory Council.
Wright AC; Beaudoin FL; McQueen RB; Yeung K; Moradi A; Herron-Smith S; Gutierrez E; Lin GA; Pearson SD
J Manag Care Spec Pharm; 2023 Jun; 29(6):692-698. PubMed ID: 37276043
[No Abstract] [Full Text] [Related]
2. Fezolinetant: First Approval.
Lee A
Drugs; 2023 Aug; 83(12):1137-1141. PubMed ID: 37462862
[TBL] [Abstract][Full Text] [Related]
3. Neurokinin Receptor Antagonist, Fezolinetant, for Treatment of Menopausal Vasomotor Symptoms.
Pinkerton JV; Redick DL; Homewood LN; Kaunitz AM
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1448-e1449. PubMed ID: 37097747
[No Abstract] [Full Text] [Related]
4. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
5. Fezolinetant (Veozah) for menopausal vasomotor symptoms.
Med Lett Drugs Ther; 2023 Jun; 65(1679):97-99. PubMed ID: 37339088
[No Abstract] [Full Text] [Related]
6. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
7. A Novel Nonhormonal Treatment for Vasomotor Symptoms of Menopause.
Javernick JA
Nurs Womens Health; 2024 Feb; 28(1):80-84. PubMed ID: 38161058
[TBL] [Abstract][Full Text] [Related]
8. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
[TBL] [Abstract][Full Text] [Related]
9. Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
Reed SD
Menopause; 2024 Apr; 31(4):245-246. PubMed ID: 38517209
[No Abstract] [Full Text] [Related]
10. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
11. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats.
Tahara A; Takamatsu H; Ohtake A; Tanaka-Amino K; Kaku S
Eur J Pharmacol; 2021 Aug; 905():174207. PubMed ID: 34048742
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
[TBL] [Abstract][Full Text] [Related]
13. Fezolinetant (Veozah) for the Treatment of Menopause Symptoms.
Crespo C; Erlich D
Am Fam Physician; 2024 Mar; 109(3):273-274. PubMed ID: 38574221
[No Abstract] [Full Text] [Related]
14. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
[TBL] [Abstract][Full Text] [Related]
15. Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Depypere H; Lademacher C; Siddiqui E; Fraser GL
Expert Opin Investig Drugs; 2021 Jul; 30(7):681-694. PubMed ID: 33724119
[No Abstract] [Full Text] [Related]
16. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal.
Gompel A; Stuenkel CA
Cell Rep Med; 2023 Jun; 4(6):101076. PubMed ID: 37343519
[TBL] [Abstract][Full Text] [Related]
18. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Neal-Perry G; Cano A; Lederman S; Nappi RE; Santoro N; Wolfman W; English M; Franklin C; Valluri U; Ottery FD
Obstet Gynecol; 2023 Apr; 141(4):737-747. PubMed ID: 36897180
[TBL] [Abstract][Full Text] [Related]
19. The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council.
Nikitin D; Lin GA; Whittington MD; Nhan E; Kayali Y; Rind DM; Pearson SD; Agboola F
J Manag Care Spec Pharm; 2024 May; 30(5):491-495. PubMed ID: 38701024
[No Abstract] [Full Text] [Related]
20. Fezolinetant.
Beninger P
Clin Ther; 2023 Aug; 45(8):802-803. PubMed ID: 37442655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
